- Study at RCSI
- Student Life
- Schools & Faculties
- Faculty of Medicine & Health Sciences
- School of Medicine
- School of Pharmacy
- School of Physiotherapy
- School of Postgraduate Studies
- School of Nursing & Midwifery
- Academic Departments
- Institute of Leadership
- Health Professions Education Centre (HPEC)
- Simulation
- Student, Academic & Regulatory Affairs
- Faculty of Sports and Exercise Medicine
- Faculty of Nursing & Midwifery
- Faculty of Dentistry
- Faculty of Radiologists
- Alumni
- Surgical Affairs
- Research & Innovation
- Innovation
- Strategic Academic Recruitment Programme
- Research News & Events
- Research Areas
- Principal Investigators
- Research Networks & Centres
- Technology Cores & Research Facilities
- Research Office
- Employment Opportunities
- PhD Projects and Postgraduate Training Opportunities
- Research Ethics
- Technology Transfer Office & Management of Intellectual Property
- Research by Faculty
- Research by Academic Department
- Research by School
- Human Resources Strategy for Researchers (HRS4R)
- About RCSI
- Council
- CEO and Senior Management
- History
- Annual Report
- Contact us and location
- Communications
- Publications
- Venue hire
- No. 26 York Street
- Athena SWAN
- RCSI and the wider community
- Quality Enhancement Office
- Academic Health Centre
- Irish Society of Urology
- Freedom of Information (FOI)
- Faculty of Medicine & Health Sciences Strategy 2013 - 2017
- Medical Validation Ireland
- Eduroam
- RCSI International
RCSI researchers Dr Leonie Young and Prof Arnold Hill awarded prestigious SFI-Pfizer Biotherapeutics Innovation Award
01 June 2016
Dr Leonie Young and Prof Arnold Hill at RCSI were one of three research groups in Ireland to receive a prestigious SFI-Pfizer Biotherapeutics Innovation Award. The Science Foundation Ireland and Pfizer funded programme provides qualified academic researchers with an opportunity to deliver important potential discoveries in the areas of immunology, oncology, cardiovascular and rare diseases. Leonie and Arnie’s work focusses on the underlying mechanisms that control breast cancer resistance to traditional chemotherapeutics. This programme provides funding for three years and will better characterize, and effectively target, treatment resistant breast cancers.